IVA
Inventiva S.A. NASDAQ Listed Jul 10, 2020$5.35
Pre-mkt
$5.77
+0.29%
Mkt Cap $278.1M
52w Low $2.85
48.7% of range
52w High $7.98
50d MA $5.73
200d MA $5.18
P/E (TTM)
-2.7x
EV/EBITDA
-5.5x
P/B
—
Debt/Equity
-2.0x
ROE
—
P/FCF
-7.3x
RSI (14)
—
ATR (14)
—
Beta
0.95
50d MA
$5.73
200d MA
$5.18
Avg Volume
389.1K
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
50 rue de Dijon · Daix, I0 21121 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.28 | -1.07 | -282.1% | 5.48 | -4.9% | +1.3% | -2.2% | +0.7% | +3.7% | -5.8% | — |
| Sep 25, 2025 | AMC | -0.41 | -1.89 | -361.7% | 6.01 | -2.8% | +0.7% | -3.0% | -1.4% | +2.1% | +6.6% | — |
| May 23, 2025 | AMC | -0.47 | -2.69 | -473.0% | 3.09 | +5.2% | +8.7% | -2.1% | +3.0% | +0.0% | +0.0% | — |
| Sep 25, 2024 | AMC | -0.56 | -1.01 | -81.1% | 2.17 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% | — |
| Mar 27, 2024 | AMC | -0.40 | -1.25 | -211.7% | 3.82 | -1.8% | -5.2% | +1.7% | -1.4% | +0.3% | +0.5% | — |
| Sep 28, 2023 | AMC | -1.27 | -1.43 | -13.1% | 4.26 | +0.7% | -1.4% | -4.0% | +2.0% | +3.4% | -3.5% | — |
| Mar 29, 2023 | AMC | -0.57 | -0.64 | -11.9% | 3.76 | -1.6% | -7.7% | +4.9% | -2.2% | -4.5% | +1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $4.06 | $3.99 | -1.7% | +3.0% | -1.2% | -6.1% | +10.8% | -6.0% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.36 | $5.00 | -6.7% | +3.2% | -17.7% | +1.3% | +7.6% | +10.3% |
| Sep 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.87 | $5.69 | -3.1% | -1.4% | +2.1% | +6.6% | +3.7% | -4.4% |
| Sep 2 | Guggenheim | Maintains | Buy → Buy | — | $6.19 | $5.49 | -11.3% | -15.0% | +9.7% | -2.9% | -0.5% | -3.6% |
| Apr 4 | Guggenheim | Maintains | Buy → Buy | — | $3.02 | $3.46 | +14.6% | +1.7% | +1.0% | -1.9% | +4.6% | -3.1% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $3.15 | +7.1% | +5.4% | -2.6% | +1.7% | +1.0% | -1.9% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.04 | $3.01 | -1.0% | -4.3% | +1.0% | +0.0% | +5.4% | -2.6% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.49 | +8.3% | +5.2% | +0.4% | +4.5% | -3.1% | +3.3% |
| Nov 22 | Stifel | Maintains | Buy → Buy | — | $2.66 | $2.56 | -3.8% | -1.5% | +1.9% | -1.1% | +1.5% | -1.1% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.67 | $2.62 | -1.9% | -2.6% | -6.9% | +0.0% | +8.7% | +3.8% |
| Sep 26 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% |
| Sep 26 | Stifel | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% |
| Apr 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.78 | $3.77 | -0.3% | +2.1% | -0.3% | +1.0% | -4.9% | -4.1% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.95 | +9.1% | +1.7% | -1.4% | +0.3% | +0.5% | +3.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.51 | +1.7% | +10.1% | -0.5% | +1.6% | -1.0% | -0.5% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.78 | +4.4% | +6.9% | -0.5% | +3.6% | -1.0% | +1.5% |
| Feb 16 | Stifel | Maintains | Buy → Buy | — | $3.94 | $3.34 | -15.2% | -16.0% | +1.5% | -2.7% | +4.0% | +0.6% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.19 | -0.2% | +3.1% | +4.4% | -2.4% | +2.7% | -0.9% |
| Sep 21 | Roth MKM | Maintains | Buy → Buy | — | $3.83 | $4.15 | +8.4% | +9.4% | +4.5% | -1.6% | +3.0% | -6.3% |
| Sep 1 | Guggenheim | Maintains | Buy → Buy | — | $3.70 | $3.77 | +1.9% | -1.1% | +7.4% | -8.1% | +6.9% | -8.3% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $3.86 | +0.0% | +4.4% | +1.5% | -0.2% | -5.6% | +2.1% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.58 | $4.51 | -1.5% | +6.6% | -2.5% | -2.1% | -4.5% | -4.5% |
| May 31 | Roth MKM | Maintains | Buy → Buy | — | $3.03 | $3.16 | +4.3% | +30.2% | -2.4% | +3.4% | -1.9% | -1.9% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.82 | $2.90 | +2.8% | +0.0% | +7.4% | +30.2% | -2.4% | +3.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.47 | $3.47 | +0.0% | +4.9% | -2.2% | -4.5% | +1.9% | -4.2% |
| Mar 17 | Stifel | Maintains | Buy → Buy | — | $4.43 | $4.68 | +5.7% | +2.9% | -6.3% | -6.3% | +1.2% | +3.1% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.90 | $3.98 | +2.1% | +0.5% | -2.8% | -3.1% | +1.3% | +2.5% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.34 | $13.75 | +3.1% | +3.1% | -0.4% | +0.5% | -2.0% | -3.0% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.20 | $13.12 | -0.6% | +1.9% | +0.0% | -0.2% | -0.3% | +1.0% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $14.50 | +4.1% | +3.0% | +1.7% | -1.8% | -1.0% | -3.8% |
| Sep 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.00 | $13.98 | -0.1% | -0.5% | +3.0% | +1.7% | -1.8% | -1.0% |
| Mar 8 | Societe Generale | Downgrade | Buy → Sell | — | $14.20 | $13.60 | -4.2% | -3.5% | -1.1% | -6.1% | +0.8% | +3.9% |
| Mar 7 | Societe Generale | Downgrade | Buy → Sell | — | — | — | — | — | — | — | — | — |
| Aug 5 | Roth Capital | Maintains | Buy → Buy | — | $10.50 | $10.90 | +3.8% | +1.6% | +6.5% | +4.5% | +2.8% | -2.0% |
| Aug 4 | Stifel | Maintains | Buy → Buy | — | $10.24 | $10.60 | +3.5% | +2.5% | +1.6% | +6.5% | +4.5% | +2.8% |
| Aug 4 | Guggenheim | Maintains | Buy → Buy | — | $10.24 | $10.60 | +3.5% | +2.5% | +1.6% | +6.5% | +4.5% | +2.8% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 11:06am
· Source: massive.com